Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.65 |
| ▸ | PPARA | Q07869 | 14/20 | 0.65 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377531 | 0.89 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL377363 | 0.89 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL2786491 | 0.86 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL7922719 | 0.85 | PPARG (0.48) | PPARGPPARA | |
| SCHEMBL7920692 | 0.83 | PPARG (0.50) | PPARGPPARAPPARD | |
| Trifluoroacetic Acid SCHEMBL7711566 | 0.83 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL7926603 | 0.81 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL2785848 | 0.80 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL7923377 | 0.80 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL6385754 | 0.79 | PPARG (0.47) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| EP-1041977-B1 | USE OF PPAR-GAMMA ACTIVATORS FOR TREATING DERMATOLOGICAL DISORDERS | GALDERMA RES & DEV (FR) | 2008-07-30 | — | — | EP | claimed |
| US-20050245473-A1 | Proliferation- and differentiation-modulating agents and uses therefor | SAUNDERS NICHOLAS A | 2005-11-03 | — | — | US | claimed |
| US-6403656-B1 | SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C (FR) | 2002-06-11 | — | — | US | claimed |
| US-20140227289-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-08-14 | — | — | US | disclosed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | disclosed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-7122564-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050245473-A1 | Proliferation- and differentiation-modulating agents and uses therefor | SAUNDERS NICHOLAS A | 2005-11-03 | — | — | US | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| US-6403656-B1 | SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.